WillItSurvive
No grouping · China

Chungui International BioTech Group Co., Ltd.

Pre-IPO Chinese cinnamon-fermentation wine maker filing for a $15M Nasdaq micro-cap listing.

Little protection left
Assessed 29 July 2026 · Evidence as of 29 July 2026
Not much stands between this business and its pressures.
On the recordSince 29 July 2026 · Checkable from date unknown, still pending as of July 2026 · Every call on the record Checkpoint: IPO pricing and Nasdaq Capital Market listing completion under ticker CQFT
The call

A 22-person cinnamon-wine startup with an unpriced IPO, no disclosed revenue, and no verified protection against copying by much larger wellness makers.

Chungui makes fermented cinnamon products for consumers in China, but it is a 22-person company with no public revenue numbers, no patents on file, and no named customer contracts anyone can verify. Copying what they do would be simple for established players like Swisse or major Chinese supplement makers, because fermentation of common spices is not a secret process and there is nothing legally blocking competitors. The only thing that could matter is if the company reveals real customer lists, actual revenue, or exclusive supply agreements in its IPO paperwork when that happens, though as of mid-2026 it remains unclear whether the IPO will even complete.

Why
01
AI pressure: None apparent. This is a wellness-wine bottler, not a software business; no AI product competes for its shelf space or customers. Could AI do the core job? Only partly.
02
Bigger players: Swisse, By-Health, Amway, Guangxi Wuzhou Zhongheng Group and other TCM/baijiu conglomerates. These bigger wellness and TCM makers could copy a cinnamon-fermentation wine easily if the niche ever became worth taking. Could a giant copy it? Yes, easily.
03
What protects it. Nothing confirmed yet: no disclosed patents, no named customers, no disclosed revenue, no supply-lock contracts.
What would change this call
Whether the IPO prices and completes on Nasdaq under ticker CQFT within the next year. Shows whether Chungui can even reach public markets and raise the $15M targeted.
Whether F-1 amendments disclose actual revenue figures or named repeat customers. Shows whether any real commercial demand exists beyond the filing narrative.
Whether Chungui discloses issued patents or an exclusive multi-year supply contract for Six-Year-Old Aged Cinnamon. Shows whether any defensible moat exists against incumbents copying the process.
Key numbers
  • $15M target raise, 3M shares at $5 each (2026-03-12)
  • Revenue not disclosed in F-1 filing (2026-03-12)
  • 22 employees reported company-wide (2026-07-12)
Named risks
  • IPO may never price; listing date still unknown as of Jul 12, 2026. Severity: high
  • Zero disclosed revenue and no verified customers or commercial partners. Severity: high
  • No confirmed patents on fermentation method, leaving no protectable IP moat. Severity: high
  • Small $15M raise and thin post-IPO float typical of volatile China micro-cap Nasdaq listings. Severity: medium
  • No canonical corporate website, founding date, or verified pre-IPO financing history. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
SwissecontestingHolds ~29% of China's health supplement market as of Jul 10, 2025, versus Chungui's zero disclosed revenue
By-Health, Amway, HerbalifecontestingDominate China's cross-border supplement e-commerce; no direct Chungui rivalry confirmed as of Jul 2026
Guangxi Wuzhou Zhongheng GroupcontestingEstablished TCM/health-food company with hospital-channel products, noted Apr 8, 2026
Huangjiu brands (Gu Yue Long Shan, Donghu Shengta, Pagoda)contestingHold 'Time-Honored Brand' heritage status in China's traditional wine market as of Jun 10, 2026
Questions people ask
Is Chungui International BioTech Group profitable?
No revenue figures have been disclosed. Chungui's March 12, 2026 F1 filing did not report revenue, and as of July 3, 2026, aggregator financial pages listed revenue, gross profit, and other income statement lines as n/a, indicating no confirmed reported revenue exists.
Has Chungui's Nasdaq IPO (ticker CQFT) actually priced yet?
No. Chungui filed its F1 on March 12, 2026 seeking $15 million via 3 million shares at $5 each, but as of July 12, 2026 the exact listing date remained unknown and the deal had not priced or completed.
Who owns and runs Chungui International BioTech?
Chungui is a privately held Cayman Islands holding company operating through China-based subsidiaries, still pre-IPO as of July 2026. Its CEO is listed as Qiugui Yang, with the company reporting 22 employees as of mid-2026.
Could AI replace Chungui International BioTech?
Chungui is a physical biofermentation and consumer-wine business, a category largely outside direct AI replacement. But as of July 2026 it has zero disclosed revenue and no verified customers, so there is effectively no established business yet for AI or anyone else to threaten.
Who is Chungui International BioTech's biggest competitor?
No source names a direct rival to Chungui's cinnamon-fermented wine niche. The closest adjacent incumbents are China's dietary-supplement giants; Swisse alone reportedly held about 29% of China's health-supplement market as of July 10, 2025.
What does Chungui International BioTech actually sell?
Chungui markets a 'medicinal-food homologous natural active nutritional wine' made from Six-Year-Old Aged Cinnamon using a proprietary 'Microbial Fan's Method' fermentation process, sold across six product systems spanning premium to mass-market price points, per its March 12, 2026 IPO filing.
Timeline
  • 2026-07-12Company profile shows 22 employees, no confirmed patents or named customers disclosed
  • 2026-07-03Aggregator shows revenue and gross profit as n/a, no confirmed financials
  • 2026-06-16Coverage confirms exact IPO listing date for CQFT still unknown
  • 2026-04-02Report frames China's wellness-alcohol market at $7.2 billion in 2025 as adjacent tailwind
  • 2026-03-12Chungui files F1 with SEC to list on Nasdaq under ticker CQFT, targeting $15M raise
  • 2025-07-10China Briefing reports Swisse holds about 29% of China's supplement market
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources